🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for PNH - Paroxysmal Nocturnal Hemoglobinuria

Long-term Safety and Tolerability of MY008211A Tablets in Patients With Paroxysmal Nocturnal Hemoglobinuria NCT06933914Phase 2, Phase 31 site📍 Tianjin Wuhan Createrna Science and Technology Co., Ltd · Tests: MY008211A tablets Global PNH Patient Registry NCT05755867n/a1 site📍 Bethesda Aplastic Anemia and MDS International Foundation Home Reported Outcomes in PNH NCT06411626n/a1 site📍 East Hanover Novartis Pharmaceuticals · Tests: PNH-relevant therapies Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH Patients NCT06934967Phase 315 sites📍 Atlanta📍 New Brunswick📍 Philadelphia Novartis Pharmaceuticals · Tests: LNP023 MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure. NCT06412497Phase 21 site📍 Minneapolis Masonic Cancer Center, University of Minnesota · Tests: Rituximab, Rabbit ATG, Cyclophosphamide, Fludarabine, Total Body Irradiation Enhancing the Clinical Management of CMF Through a National Pediatric and Adult Network Based on Biological and Genetic Data NCT07877727n/a4 sites📍 Avellino📍 Genova📍 Naples Istituto Giannina Gaslini Study of Safety and Efficacy of HS-10542 in Patients With Paroxysmal Nocturnal Hemoglobinuria NCT07470762Phase 1, Phase 21 site📍 Hangzhou Jiangsu Hansoh Pharmaceutical Co., Ltd. · Tests: HS-10542, HS-10542, HS-10542 REAL-CARE: Real-world Effectiveness of Iptacopan in Italian Patients With Paroxysmal Nocturnal Hemoglobinuria NCT07229235n/a12 sites📍 Alessandria📍 Avellino📍 Brescia Novartis Pharmaceuticals A Phase I Clinical Trial to Evaluate CMS-D017 Following Single and Multiple Doses in Healthy Participants NCT07462780Phase 11 site📍 Beijing Shenzhen Kangzhe Biotechnology Co., Ltd. · Tests: CMS-D017 Capsule, CMS-D017 Placebo Capsule, CMS-D017 Capsule, CMS-D017 Placebo Capsule Study of Safety and Efficacy of MY008211A in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor Therapy NCT06932744Phase 32 sites📍 Beijing📍 Tianjin Wuhan Createrna Science and Technology Co., Ltd · Tests: MY008211A tablets, Eculizumab Injection Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells and Post-transplant Cyclophosphamide for GVHD Prophylaxis NCT03520647Phase 21 site📍 Bethesda National Heart, Lung, and Blood Institute (NHLBI) · Tests: Cyclophosphamide, Peripheral Blood Stem Cells Danicopan PMS in Korea NCT07457151n/a4 sites📍 Busan📍 Hwasun-gun📍 Seoul AstraZeneca To Evaluate Safety, Tolerability, PK/PD & Food Effect of Single/Multiple Oral TUL321 Capsules in Healthy Participants. NCT07760467Phase 11 site📍 Changsha Zhuhai United Laboratories Co., Ltd. · Tests: Part1: TUL321, Part1: Placebo, Part2: TUL321, Part2: Placebo A First-in-Human Safety and Efficacy Study of ALN-CFB, a Small Interfering RNA (siRNA) Targeting Complement Factor B, in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria With Persistent Anemia on a C5 Inhibitor NCT07187401Phase 1, Phase 28 sites📍 Toronto📍 Suwon📍 Seoul Regeneron Pharmaceuticals · Tests: ALN-CFB, Placebo Study of Safety and Efficacy of MY008211A in Patients With Residual Anemia Despite Anti-C5 Antibody Treatment NCT06932471Phase 31 site📍 Beijing Wuhan Createrna Science and Technology Co., Ltd · Tests: MY008211A tablets A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works NCT05744921Phase 348 sites📍 São Paulo📍 Toronto📍 Medellín Regeneron Pharmaceuticals · Tests: Pozelimab, Cemdisiran Investigation of Pharmacokinetics,Safety,and Pharmacodynamics of HSK39297 in Subjects With Hepatic Impairment NCT07152288Phase 11 site📍 Beijing Haisco Pharmaceutical Group Co., Ltd. · Tests: HSK39297 tablets, HSK39297 tablets, HSK39297 tablets Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis NCT06449001Phase 34 sites📍 Saskatoon📍 Paris📍 Leeds Alexion Pharmaceuticals, Inc. · Tests: Danicopan Study of Ultomiris® (Ravulizumab) Safety in Pregnancy NCT06312644n/a7 sites📍 Boston📍 Melbourne📍 Paris Alexion Pharmaceuticals, Inc. · Tests: Ultomiris National Longitudinal Cohort of Hematological Diseases NCT04645199n/a1 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China Long-term Safety and Tolerability of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria NCT06745622Phase 21 site📍 Nanjing Haisco Pharmaceutical Group Co., Ltd. · Tests: HSK39297 tablets A Phase II Study Evaluating the Efficacy and Safety of XH-S003 Capsules in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) NCT06978699Phase 21 site📍 Tianjin S-INFINITY Pharmaceuticals Co., Ltd · Tests: XH-S003 Capsule A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) NCT04901936Phase 212 sites📍 Atlanta📍 Prague📍 Paris Apellis Pharmaceuticals, Inc. · Tests: Pegcetacoplan Safety, Tolerability, PK and PD of ADX-038 in Healthy Participants and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients NCT05876312Phase 1, Phase 24 sites📍 Brisbane📍 Melbourne📍 Parkville ADARx Pharmaceuticals, Inc. · Tests: ADX-038, Placebo A Multi-center, Ambispective Cohort Study to Evaluate the Impact of Iptacopan for Adult Patients With PNH in China NCT06931691n/a14 sites📍 Hefei📍 Guangzhou📍 Guangzhou Novartis Pharmaceuticals · Tests: LNP023 The International PNH Interest Group PNH Registry NCT06524726n/a1 site📍 Altamonte Springs International PNH Interest Group Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells NCT01174108Phase 22 sites📍 Baltimore📍 Bethesda National Heart, Lung, and Blood Institute (NHLBI) · Tests: Miltenyi CD34 Reagent System, Donor derived G-CSF mobilized PBC A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Efficiently NCT07154745Phase 320 sites📍 Ribeirão Preto📍 Santo André📍 São Paulo Regeneron Pharmaceuticals · Tests: Pozelimab, Cemdisiran A Phase Ib, Multicenter, Open-Label Study of Multiple-Dose EA5 in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH) NCT07256301Phase 12 sites📍 Tianjin📍 Hangzhou Shanghai Lanyi Therapeutics Co., Ltd. · Tests: EA5 A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy NCT07416162n/a3 sites📍 Jeollanam📍 Seoul📍 Seoul Novartis Pharmaceuticals
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy